Eli Lilly will raise the UK list price of its weight-loss and type 2 diabetes treatment Mounjaro by up to 170% to be in line with other European markets, it said on Thursday, as the pharma industry responds to U.

Eli Lilly is set to increase the UK price of its weight-loss and diabetes drug Mounjaro by 170%, aligning it with other European markets. Originally underpriced for NHS accessibility, Mounjaro has now surpassed rival Wegovy in UK sales.

Eli Lilly & Co. is raising the list price for its obesity shot in the UK, as the pharma industry comes under pressure from US President Donald Trump to increase medicine prices in Europe and lower them for Americans.

Eli Lilly ( NYSE: LLY) will raise the cost of its GLP-1/GIP receptor agonist Mounjaro (tirzepatide), approved for type 2 diabetes, by up to 170% in the UK starting in September. The move comes as President Donald Trump has put pressure on pharma companies to align US drug prices to what they are in other parts of the world.

Eli Lilly will increase the UK price of its Mounjaro treatment by 170% to match European markets. Despite Novo Nordisk's initial market lead with Wegovy, Mounjaro's sales have surged. The NHS will maintain access to the drug despite the price hike,

Investing.com -- Eli Lilly (NYSE:LLY) has increased the price of its weight loss drug Mounjaro in the United Kingdom by up to 170%, according to the Financial Times on Thursday. The pharmaceutical company’s price for a month’s supply of the highest doses of Mounjaro will rise from £122 to £330, the FT reported.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials. The weight loss pill also significantly improved heart health markers like cholesterol and blood pressure.